Cox-2 inhibition enhances the activity of sunitinib in human renal cell carcinoma xenografts
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Cox-2 inhibition enhances the activity of sunitinib in human renal cell carcinoma xenografts
Authors
Keywords
-
Journal
BRITISH JOURNAL OF CANCER
Volume 108, Issue 2, Pages 319-326
Publisher
Springer Nature
Online
2013-01-16
DOI
10.1038/bjc.2012.591
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- COX-2 as a target for cancer chemotherapy
- (2014) Nilanjan Ghosh et al. Pharmacological Reports
- Antitumor Activity and Safety of Tivozanib (AV-951) in a Phase II Randomized Discontinuation Trial in Patients With Renal Cell Carcinoma
- (2012) Dmitry A. Nosov et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase II Trial of Sunitinib on an Intermittent Versus Continuous Dosing Schedule As First-Line Therapy for Advanced Renal Cell Carcinoma
- (2012) Robert J. Motzer et al. JOURNAL OF CLINICAL ONCOLOGY
- Celecoxib, a cyclooxygenase-2 inhibitor, potentiates the chemotherapic effect of vinorelbine in the medullary thyroid cancer TT cell line
- (2012) A. Vivaldi et al. MOLECULAR AND CELLULAR ENDOCRINOLOGY
- Phase II study of the combination carboplatin plus celecoxib in heavily pre-treated recurrent ovarian cancer patients
- (2011) Francesco Legge et al. BMC CANCER
- Combined Effects of Cyclooxygenase-1 and Cyclooxygenase-2 Selective Inhibitors on Ovarian Carcinoma in Vivo
- (2011) Wei Li et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Clinical and Immunomodulatory Effects of Celecoxib Plus Interferon-Alpha in Metastatic Renal Cell Carcinoma Patients with COX-2 Tumor Immunostaining
- (2011) Anita Schwandt et al. JOURNAL OF CLINICAL IMMUNOLOGY
- Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial
- (2011) Brian I Rini et al. LANCET
- Resistance of Renal Cell Carcinoma to Sorafenib Is Mediated by Potentially Reversible Gene Expression
- (2011) Liang Zhang et al. PLoS One
- COX-2 inhibition improves immunotherapy and is associated with decreased numbers of myeloid-derived suppressor cells in mesothelioma. Celecoxib influences MDSC function
- (2010) Joris D Veltman et al. BMC CANCER
- Biomarker-based phase I dose-escalation, pharmacokinetic, and pharmacodynamic study of oral apricoxib in combination with erlotinib in advanced nonsmall cell lung cancer
- (2010) Karen Reckamp et al. CANCER
- Interleukin-8 Mediates Resistance to Antiangiogenic Agent Sunitinib in Renal Cell Carcinoma
- (2010) D. Huang et al. CANCER RESEARCH
- Development and Characterization of Clinically Relevant Tumor Models From Patients With Renal Cell Carcinoma
- (2010) Jose A. Karam et al. EUROPEAN UROLOGY
- Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial
- (2010) Cora N. Sternberg et al. JOURNAL OF CLINICAL ONCOLOGY
- Reversible Epithelial to Mesenchymal Transition and Acquired Resistance to Sunitinib in Patients with Renal Cell Carcinoma: Evidence from a Xenograft Study
- (2010) H. J. Hammers et al. MOLECULAR CANCER THERAPEUTICS
- Renal Cancer Resistance to Antiangiogenic Therapy Is Delayed by Restoration of Angiostatic Signaling
- (2010) R. S. Bhatt et al. MOLECULAR CANCER THERAPEUTICS
- Enhancement of the Sensitivity of Renal Cell Carcinoma Cells to Fas-Mediated Cytotoxicity and Apoptosis by the Selective Cyclooxygenase-2 Inhibitor JTE-522
- (2010) Nodoka Sato et al. UROLOGIA INTERNATIONALIS
- Multicenter Phase II Trial of Combination Therapy with Meloxicam, a COX-2 Inhibitor, and Natural Interferon- for Metastatic Renal Cell Carcinoma
- (2009) N. Shinohara et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma
- (2009) Robert J. Motzer et al. JOURNAL OF CLINICAL ONCOLOGY
- Resistance to targeted therapy in renal-cell carcinoma
- (2009) Brian I Rini et al. LANCET ONCOLOGY
- Does Arterial Spin-labeling MR Imaging–measured Tumor Perfusion Correlate with Renal Cell Cancer Response to Antiangiogenic Therapy in a Mouse Model?
- (2009) Rachel Schor-Bardach et al. RADIOLOGY
- The prognostic value of peritumoral regulatory T cells and its correlation with intratumoral cyclooxygenase-2 expression in clear cell renal cell carcinoma
- (2008) Jin F. Li et al. BJU INTERNATIONAL
- Antitumor enhancement of celecoxib, a selective Cyclooxygenase-2 inhibitor, in a Lewis lung carcinoma expressing Cyclooxygenase-2
- (2008) Won Park et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now